{
  "docId": "019de075-e1f8-726f-9315-81fdfad7abab",
  "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Spyre Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 37,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The chart plots UC maintenance remission rates against maintenance dosing frequency, showing current standard-of-care drugs clustered at lower efficacy and higher frequency, while the 'Spyre Target' is positioned at higher efficacy and lower frequency.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/5",
  "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab",
  "deckJsonHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab.json",
  "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.58,
        "x": 0.37,
        "y": 0.25
      },
      "kind": "chart",
      "text": "UC MAINTENANCE REMISSION RATES (%) vs MAINTENANCE DOSING FREQUENCY (WEEKS)",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6d0a16c-a593-4497-a64e-055d729b00e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.32,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "UNMET NEED\n~1.7 million individuals are currently diagnosed with IBD in the U.S.\nThere remain substantial unmet needs in IBD management, including:\nInadequate response or loss of response to existing therapies\nSide effects and safety concerns associated with long-term medication use\nAdherence to frequent and/or inconvenient dosing regimens",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0754b631-b666-40fc-9135-d878e98519e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.03,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "Source: 1Crohn's and Colitis Foundation. Summary data for select agents that randomize patients post response to induction; data from labels, company reports. Vedolizumab approved in US as Q8W IV – Q2W SC approval pending following CRL in 2019. TL1A maintenance data not available. Orals not shown (pbo-adj maintenance remission rates): Jaks - tofacitinib (27%), upadacitinib (30% 15mg, 40% 30mg); S1Ps: ozanimod (19%); etrasimod (25% - P3 treat-through design).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0c6d4fb-77a3-481c-9093-9766ff762f69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Despite advances, new approaches are needed to break the efficacy ceiling and improve convenience of biologics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "077c36d6-be53-4837-840a-7b7e8d69a72c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "75d8ab5b-20ce-45ef-9ba3-22bfb093916a",
      "evidence": "The slide describes 'UNMET NEED' and lists specific needs in IBD management.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "c75d2507-8482-44e8-b4c1-b2c46943f3f3",
      "evidence": "Contrasts current standard of care limitations with the desired future state (Spyre Target).",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 5,
      "from": 5,
      "beatId": "8c6ed229-d96c-429b-bd2d-60c9ffc643e0",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document presents a clear problem statement on page 5",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b7091b28-a531-4677-b268-c8e3a5804fd9",
      "evidence": "The problem statement on page 5 sets up the need for improved treatment",
      "position": 0,
      "objective": "What are the consequences of not improving IBD treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}